Effects of ethyl pyruvate in the treatment of hyperkinetic pulmonary hypertension

Mengmeng TANG,Nwa JIN,Chuanzhen LIU,Kai LIU,Guangqing CAO,He WANG,Xinyan PANG,Shuming WU

DOI: https://doi.org/10.6040/j.issn.1671-7554.0.2015.107

2015-01-01

Abstract:Objective To evaluate the effects of ethyl pyruvate (EP)on hyperkinetic pulmonary arterial hypertension (PAH).Methods Rat hyperkinetic PAH models were established by shunting common carotid artery and internal jug-ular vein.After that,30 rat models were randomly divided into 3 groups,with 10 rats in each group:EP treatment group,control group,and shunt group.Another 10 rats were enrolled in the sham-operation group as negative controls. Rats in the EP treatment group were given intraperitoneal injection of EP [50 mg /(kg·d)]for 30 days,and rats in the control group were injected with the same volume of normal saline.The systolic pulmonary arterial pressure (SPAP) was measured after that and then the right ventricular hypertrophy index (RVHI)was calculated after the heart was removed.The percentage of diameter thickness (WT%)and wall area (WA%)were calculated in lung tissues stained with HE.The levels of TNF-αand IL-6 in the serum were measured with ELISA and expression of NF-κB p65 in lung tissues was detected with Western blotting.Results Compared with shunt group,EP treatment group had significantly decreased SPAP,RVHI,WT%,WA%,the levels of TNF-αand IL-6 in serum,and expression of NF-κB p65 in lung tissues.Conclusion EP could ameliorate PAH and inhibit the remodeling of pulmonary blood vessels in hyperkinetic PAH rats by reducing the expression of NF-κB p65,synthesis and release of cytokines (TNF-α,IL-6,etc.)and alle-viate inflammation reaction.